WHITE PAPER

DATA MONETIZATION FOR MEDTECH COMPANIES: FROM DEVICE SALES TO DATA-DRIVEN REVENUE

1. Executive Summary

The MedTech industry is at a pivotal inflection point where data is becoming as valuable as the devices themselves. As connected medical technologies proliferate, global MedTech companies are strategically turning to data monetization to unlock new, recurring revenue streams, deliver superior clinical value, and strengthen critical relationships with payers and providers. This white paper explores six emerging monetization models—ranging from embedded digital services to sophisticated analytics platforms and data marketplaces.

Supported by real-world case studies from industry leaders like Medtronic, ResMed, and Roche, this paper provides a practical framework for navigating the significant opportunities in this space. With the global healthcare data monetization market projected to grow from USD 0.41 billion in 2022 to USD 1.62 billion by 2030, the stakes are exceptionally high. We will examine the market dynamics, regulatory enablers, and strategic challenges, offering actionable recommendations for MedTech leaders aiming to position their firms as pioneers in the burgeoning data economy.

Infosys®
Navigate your next

Table of Contents

2. Introduction: The Digital Shift in MedTech

Medical technology companies are undergoing a fundamental transformation, evolving beyond traditional device manufacturing to become data-centric solution providers. The rapid integration of connected devices, remote monitoring technologies, and AI-driven diagnostics has enabled MedTech firms to generate vast volumes of real-time patient and operational data. This data has emerged as a strategic asset capable of unlocking new revenue streams, improving clinical outcomes, and forging powerful partnerships with payers.

Unlike the traditional, transactional model of hardware sales, data monetization provides a pathway to recurring, service-based income while directly supporting the industry-wide shift toward value-based care. The timing for this transition is optimal. Regulatory bodies like the FDA in the United States and frameworks like the EU's Medical Device Regulation (MDR) and Germany's Digital Health Applications (DiGA) are creating clearer pathways for digital health innovation. Concurrently, healthcare systems are increasingly embracing real-world evidence to inform clinical and financial decisions.

This white paper examines the core data monetization models being successfully deployed in the MedTech industry. It provides an analysis of market dynamics, explores real-world case studies, and delivers strategic insights into the risks, enablers, and actionable steps needed to succeed. The goal is to equip MedTech leaders with the knowledge to build a robust, ethical, and profitable data strategy.

3. Market Context and Key Drivers

3.1 Market Size and Projected Growth

The healthcare data monetization market is experiencing exponential growth, fueled by the proliferation of connected medical devices and the increasing value of real-world health data. Estimated at just under half a billion USD in 2022, the global market is projected to surpass USD 1.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.8%. This rapid expansion reflects a foundational shift toward data-driven healthcare and the pursuit of more sustainable, recurring revenue models. North America currently leads the market, benefiting from a mature digital health infrastructure and strong payer incentives. However, the Asia-Pacific region is the fastest-growing, driven by widespread digital transformation and rising healthcare investments.

3.2 Key Market Drivers

Several powerful forces are converging to accelerate the adoption of data monetization in MedTech:

Explosion of Healthcare Data

The widespread adoption of wearable devices, remote monitoring systems, and electronic health records (EHRs) is generating unprecedented volumes of actionable health data.

Alignment with Value-Based Care

Health systems and insurers are increasingly incentivizing outcomes-based models. Data from connected devices is crucial for remote monitoring, preventive care, and tracking therapy adherence, making it central to these new reimbursement structures.

Demand for Real-World Evidence (RWE)

Pharmaceutical companies and clinical research organizations actively seek real-world insights to optimize drug development, conduct post-market surveillance, and validate therapeutic efficacy.

Technological Advancements

The maturity of cloud computing, artificial intelligence (AI), and interoperable platforms has made it possible to implement scalable, secure, and actionable data monetization strategies.

Regulatory Evolution

Modern regulations are becoming increasingly supportive of ethical data usage, interoperability, and digital innovation, creating a more favorable environment for data-centric business models.

3.3 Critical Challenges and Constraints

Despite the significant momentum, MedTech companies must navigate several critical hurdles to achieve sustainable and compliant growth:

Data Privacy and Consent

- Ensuring informed, explicit, and revocable consent is resource-intensive—especially under GDPR and HIPAA.
- Differentiating consent for primary care vs. secondary monetization use is often misunderstood or mishandled.

Regulatory Uncertainty

- Multi-region operations must navigate overlapping and evolving laws (e.g., EU MDR, U.S. Cures Act, GDPR).
- Ambiguity around secondary data usage and clinical validation of digital solutions delays deployment.

Interoperability Gaps

- Device-generated data often exists in proprietary formats.
- Lack of FHIR/API standards adoption slows integration with EHRs, payer systems, and third-party analytics platforms.

Cybersecurity & Data Breach Risk

- Monetizing data increases exposure to cyber threats.
- Firms must invest heavily in encryption, zero-trust frameworks, and breach response to protect brand and liability.

Business Model Limitations

- Subscription fatigue among clinicians and providers can limit uptake.
- Demonstrating clear ROI from analytics or data sharing is a challenge, especially for payers.

Ethical and Public Perception Risks

- Patients may distrust commercial use of their data, even if anonymized.
- Transparency, communication, and ethics frameworks are essential to maintain trust.

4. Six Core Data Monetization Models for MedTech

MedTech companies are moving beyond traditional device sales by unlocking recurring revenue streams through innovative data-driven models. The following six models represent the primary pathways reshaping the industry's economic landscape.

4.1 Embedded and Add-on Digital Services

This model involves integrating digital features—such as real-time monitoring, alerts, or clinical decision-support tools—directly into a device's ecosystem. These services are often bundled with the hardware or offered as premium, subscription-based add-ons. For example, a continuous glucose monitor paired with a companion app that tracks trends and shares automated reports with clinicians. The revenue model is typically based on monthly or annual subscriptions, tiered access levels, or comprehensive device-as-a-service packages.

4.2 Outcome-Based Reimbursement

This model directly links a company's revenue to patient health outcomes, which are captured and verified by data from medical devices. Payers, such as insurance companies, reimburse the MedTech firm based on predefined metrics like improved therapy adherence, reduced hospital readmission rates, or faster recovery times. A prominent example is the use of sleep apnea devices that report usage data to payers to qualify for ongoing reimbursement, thereby aligning financial incentives with clinical goals.

4.3 Direct Data Licensing and Subscriptions

In this model, de-identified and aggregated data collected from devices is licensed to third parties. These customers are often pharmaceutical companies, research institutions, or other health-tech firms seeking real-world evidence for trend analysis, clinical trial design, or post-market surveillance. For instance, a company might license anonymized, patient-reported outcome data to a pharmaceutical partner to monitor a new drug's effectiveness in a real-world setting. Revenue is generated through subscriptions, one-time licensing fees, or sales of specific data packs.

4.4 Data Marketplaces and Exchanges

MedTech firms can participate in secure, regulated platforms where anonymized datasets can be exchanged or sold under tightly controlled access. This model fosters scalability and enables broader collaboration with a diverse range of partners without the need to build direct, one-to-one relationships for every transaction. An example would be a manufacturer of oncology devices contributing data to a third-party health data marketplace, where it can be accessed by researchers studying cancer treatment efficacy. Revenue is generated through licensing fees, access subscriptions, or usage-based pricing managed by the platform.

4.5 Analytics-as-a-Service (AaaS)

Here, MedTech companies offer actionable insights—not just raw data—by leveraging AI and advanced analytics. Customers such as hospitals, insurers, or pharmaceutical firms subscribe to access dashboards, predictive models, or customized reports that deliver high clinical or operational value. A practical application is a predictive analytics platform that uses device data to identify patients at high risk of hospital readmission, allowing care teams to intervene proactively. Revenue models include annual software licensing, pay-per-insight analytics, or tiered service plans.

4.6 Digital Therapeutics (DTx)

Digital therapeutics are software-based interventions, often delivered via mobile apps, that are designed to prevent, manage, or treat a medical condition. These products must demonstrate clinical efficacy and are often prescribed by healthcare providers. A DTx can operate as a standalone therapy or be used alongside a physical medical device. For example, a cognitive-behavioral therapy app for insomnia might be prescribed in conjunction with a sleep monitoring device. Revenue is generated through direct-to-consumer sales, reimbursement from payers, or co-marketing partnerships with pharmaceutical companies.

Monetization Models

Model	Internal Use	External Monetization
Embedded/Add-on Services	Improves product performance, patient engagement, device differentiation	Charged as premium features, bundled upgrades, or monthly service fees (e.g., $10–30/month per user)
Outcome-Based Reimbursement	Tracks real-time health outcomes to validate efficacy and device value	Reimbursement from payers based on results (e.g., improved adherence, reduced readmissions)
Data Licensing & Subscriptions	Aggregate anonymized datasets to refine R&D, product development	Sold to pharma/researchers via subscription or per-dataset fees (e.g., $100k–$500k/year for RWE access)
Data Marketplaces	Use for benchmarking or strategic partnerships	License data to third parties; pricing varies by volume, quality, and exclusivity
Analytics-as-a-Service	Run internal predictive models (e.g., device failure, patient risk scoring)	Hospitals/payers pay for insights platform—can range $50k–$200k annually
Digital Therapeutics (DTx)	Enhances product value, improves outcomes through behavioral intervention	Direct-to-consumer ($20–50/month) or insurer-reimbursed (~$200–$1,000 per user annually)

5. Strategic and Financial Impact of Data Monetization

The shift toward data-driven business models has a profound impact on the strategic and financial health of MedTech companies. It represents a move from a transactional past to a relational, service-oriented future.

5.1 The Shift from Product to Platform Revenue

Data monetization facilitates a critical transition from relying on single, high-value device sales to generating recurring, predictable revenue streams. By embedding data services or offering analytics platforms, companies create long-term customer relationships and significantly increase the lifetime value of each device. This platform-based approach transforms the business model from one-time transactions to a continuous cycle of service delivery, software updates, and value creation through subscriptions and outcome-based payments.

5.2 Diversifying Revenue and Enhancing Partnerships

Data opens up multiple new income sources beyond the core device, including subscription-based analytics, data licensing to life sciences companies, and remote monitoring services reimbursed by insurers. This diversification strengthens financial resilience. Furthermore, data that demonstrates improved patient outcomes becomes a powerful tool for negotiating value-based reimbursement models with payers. By proving a reduction in hospitalizations or an improvement in patient adherence, MedTech firms can position themselves as indispensable partners in delivering cost-effective care.

5.3 Achieving Competitive Differentiation

In a crowded market, firms that effectively leverage device-generated data can create a significant competitive moat. Data-driven insights add tangible clinical value, fostering stronger customer loyalty and making it more difficult for competitors to displace an incumbent solution. This data can also be used to prove the effectiveness of a device, accelerating market expansion and securing favorable formulary placement. Finally, a strong portfolio of data-driven intellectual property and a proven recurring revenue model can substantially increase a company's valuation in the context of mergers, acquisitions, or capital raising.

6. Industry Case Studies: Monetization in Action

Company	Monetization Model	Data Use Case	Revenue Mechanism
Medtronic – CareLink™ Network	Embedded Services	Remote monitoring of cardiac devices, providing physicians with real-time patient data.	Subscription fees are often bundled with the high-value devices, encouraging provider adoption.
ResMed – AirView & myAir	Outcome-Based Reimbursement	Tracking sleep apnea therapy compliance to ensure patients meet payer requirements.	Direct reimbursement from payers is contingent on achieving predefined adherence targets.
Masimo – SafetyNet™	Analytics-as-a-Service	Remote monitoring of post-operative patients, providing hospitals with alerts and trend data.	Hospitals subscribe to the service to reduce ICU costs and improve patient outcomes.
Roche – Flatiron Health	Data Licensing & Marketplace	Aggregating and selling de-identified oncology data for real-world evidence studies.	Internal R&D use is supplemented by selling insights to pharmaceutical companies.
PatientsLikeMe	Direct Data Licensing	Aggregating patient-reported outcomes and device data for research.	Pharmaceutical firms subscribe to access real-world evidence for clinical trial design and R&D.

7. Actionable Recommendations for MedTech Leaders

Transitioning to a data-driven business model requires a deliberate and strategic approach. The following recommendations provide a roadmap for MedTech leaders.

7.1 Align Monetization Models with Business Strategy

First, evaluate which monetization model—or combination of models—best aligns with your product lifecycle, customer base, and digital maturity. A company with a large installed base of connected devices may be well-positioned for an embedded services model, while a firm with unique clinical data might prioritize data licensing. It is often wise to pilot hybrid models, such as offering a basic embedded service for free while charging for an advanced analytics dashboard, to test market appetite and refine the value proposition.

7.2 Build a Privacy-First Data Architecture

Compliance must be a foundational element of your data strategy, not an afterthought. Embed privacy and security principles into your data architecture from the outset, ensuring adherence to regulations like GDPR, HIPAA, and MDR. Invest in robust anonymization, encryption, and consent-tracking tools to support ethical and scalable monetization. A privacy-first approach not only mitigates risk but also builds essential trust with patients and partners.

7.3 Strengthen Interoperability for Seamless Integration

The value of your data is magnified when it can be easily integrated into broader healthcare workflows. Adopt open APIs and modern data standards like FHIR to ensure your platform can connect seamlessly with EHRs, payer systems, and third-party analytics providers. A cloud-native infrastructure is essential for achieving the scalability, security, and flexibility required to succeed in a connected ecosystem.

7.4 Invest in Data Science and AI Capabilities

Raw data has limited value; its true potential is unlocked through advanced analytics. Build or acquire data science talent to develop predictive models and generate actionable insights that solve real problems for providers and payers. These insights can be bundled as a premium service, used to power clinical decision-support tools, or form the basis of an Analytics-as-a-Service offering.

7.5 Engage Regulators and Payers Early and Often

Do not develop your data monetization strategy in a vacuum. Proactively engage with regulators and payers to co-develop strategies that align with public health objectives and established reimbursement frameworks. By working collaboratively, you can ensure your solutions meet regulatory requirements and demonstrate the clinical and economic impact needed to secure favorable reimbursement and licensing agreements.

8. Conclusion: The Strategic Imperative of Data

Data monetization is no longer an optional or experimental venture for MedTech companies; it has become a strategic imperative for achieving sustainable growth, strengthening payer alignment, and creating durable product differentiation. As the broader healthcare industry continues its shift toward value-based models and digital-first ecosystems, MedTech firms must accelerate their evolution from pure device manufacturers to data-powered solution providers.

This white paper has outlined six viable pathways for monetization, supported by real-world examples and regulatory context. By thoughtfully aligning these models with core business goals, investing in a compliance-ready data infrastructure, and relentlessly focusing on outcome-driven innovation, MedTech companies can unlock significant clinical, financial, and competitive value. The time is now for leaders to operationalize their data strategy not merely as a technical upgrade, but as the core engine of their business transformation.

9. About the Author

Girish Krishnamurthy

Senior Industry Principal, Infosys Limited

10. References

- Grand View Research. (n.d.). Data monetization in healthcare. https://www.grandviewresearch.com/industry-analysis/data-monetization-healthcare-market-report
- MarketsandMarkets. (2024). Healthcare data monetization market worth $1.16 billion by 2030. https://www.prnewswire.com/news-releases/healthcare-data-monetization-market-worth-us1-16-billion-by-2030-with-14-9-cagr--marketsandmarkets-302484943.html
- Global Market Insights. (n.d.). Healthcare data monetization market analysis. https://www.gminsights.com/industry-analysis/healthcare-data-monetization-market
- GlobeNewswire. (2024). Healthcare data monetization market to showcase 18.8% CAGR. https://www.globenewswire.com/news-release/2024/04/11/2861718/28124/en/Healthcare-Data-Monetization-Market-to-Showcase-an-18-8-CAGR-During-2024-2030-Detailed-Profiles-of-Oracle-Microsoft-Google-Salesforce-SAS-Institute-TIBCO-Software-and-Sisense.html
- Market.us. (n.d.). Healthcare data monetization market news. https://media.market.us/healthcare-data-monetization-market-news/
- Wikipedia. (n.d.). Masimo SafetyNet™. https://en.wikipedia.org/wiki/Masimo
- Masimo. (n.d.). Investor relations. https://investor.masimo.com
- ResMed. (n.d.). Remote monitoring and PAP therapy adherence. https://investor.resmed.com/news-events/press-releases/detail/151/resmed-studies-show-remote-monitoring-and-automated-resupply-improve-adherence-to-pap-therapy
- Harvard Digital Platform. (n.d.). Roche–Flatiron case study. https://d3.harvard.edu/platform-digit/submission/flatiron-health-solving-cancer-through-data-analytics/
- Medtronic. (2023). CareLink™ earnings presentation. https://filecache.investorroom.com/mr5ir_medtronic/529/Earnings%20Presentation-FY23Q3-FINAL.pdf
- Medtronic Diabetes. (n.d.). CareLink™ software guide. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/workbooks/CareLink-Software-Report-Reference-Guide.pdf
- PatientsLikeMe. (n.d.). Healthcare data monetization insights. https://media.market.us/healthcare-data-monetization-market-news/

For more information, contact askus@infosys.com

Infosys®
Navigate your next